Abrilumab
Abrilumab (pronounced as ab-ri-lu-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a type of biologic therapy that targets and inhibits the function of a specific protein in the body.
Etymology
The name "Abrilumab" is derived from the Latin word "abri", meaning "to open", and "lumab", a common suffix for monoclonal antibodies. This reflects the drug's mechanism of action, which involves opening up pathways in the immune system to reduce inflammation.
Mechanism of Action
Abrilumab works by binding to the alpha4-beta7 integrin, a protein found on the surface of certain immune cells. By blocking this protein, Abrilumab prevents these cells from migrating to areas of inflammation in the body, thereby reducing symptoms of autoimmune diseases.
Uses
Abrilumab is currently being investigated for use in several autoimmune diseases, including Ulcerative Colitis and Crohn's Disease. It has shown promise in early clinical trials, but further research is needed to confirm its efficacy and safety.
Related Terms
- Monoclonal Antibody
- Autoimmune Disease
- Biologic Therapy
- Inflammation
- Ulcerative Colitis
- Crohn's Disease
See Also
External links
- Medical encyclopedia article on Abrilumab
- Wikipedia's article - Abrilumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski